Menu
Search
|

Menu

Close
X

Deciphera Pharmaceuticals Inc DCPH.OQ (NASDAQ Stock Exchange Global Select Market)

20.96 USD
+0.96 (+4.80%)
As of 2:29 AM IST
chart
Previous Close 20.00
Open 20.32
Volume 131,596
3m Avg Volume 61,315
Today’s High 21.61
Today’s Low 19.57
52 Week High 45.61
52 Week Low 15.37
Shares Outstanding (mil) 37.66
Market Capitalization (mil) 753.14
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.09 Mean rating from 11 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
EPS (USD)
FY18
-1.953
FY17
-1.639
FY16
-3.611
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.57
Price to Sales (TTM)
vs sector
--
15.43
Price to Book (MRQ)
vs sector
2.43
4.06
Price to Cash Flow (TTM)
vs sector
--
21.23
Total Debt to Equity (MRQ)
vs sector
0.43
14.84
LT Debt to Equity (MRQ)
vs sector
0.37
11.13
Return on Investment (TTM)
vs sector
-43.08
12.77
Return on Equity (TTM)
vs sector
-123.84
14.47

EXECUTIVE LEADERSHIP

Michael Taylor
President, Chief Executive Officer, Director, Since 2014
Salary: $430,400.00
Bonus: $220,000.00
Daniel Flynn
Founder, Chief Scientific Officer, Since 2014
Salary: $343,750.00
Bonus: $124,000.00
Thomas Kelly
Chief Financial Officer, Since 2015
Salary: --
Bonus: --
Christopher Morl
Chief Business Officer, Since 2016
Salary: $328,250.00
Bonus: $115,000.00
Oliver Rosen
Chief Medical Officer, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

500 Totten Pond Rd
WALTHAM   MA   02451-1916

Phone: +1781.2096400

Deciphera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases. DCC-2618, an orally administered kinase switch control inhibitor, for the treatment of gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, including glioblastoma multiforme (GBM), and other solid tumors driven by pan-KIT or PDGFR alpha. DCC-3014 is an orally administered, potent and highly selective inhibitor of colony stimulating factor receptor 1 (CSF1R). Rebastinib is an orally administered, potent and selective inhibitor of the TIE2 immunokinase. Rebastinib binds potently into the switch pocket of TIE2, stabilizing the inhibitory switch and displacing the activation switch to block TIE2 signaling.

SPONSORED STORIES